Welcome to our dedicated page for Healthcare Triangle SEC filings (Ticker: HCTI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Healthcare Triangle, Inc. filings document material-event reporting, shareholder voting matters, capital-structure changes, acquisition records, and governance disclosures for a healthcare information technology company. Recent 8-K filings cover the company’s Nasdaq-listed common stock, emerging growth company status, board-approved share repurchase program, and the completed reverse stock split reflected in amendments to its certificate of incorporation.
The filing record also includes proxy materials for a special stockholder meeting and material-agreement disclosures tied to subsidiary transactions. An amended 8-K provides acquired-business financial statements and pro forma financial information for Teyamé 360 S.L. and Datono Mediación S.L., connecting transaction disclosures with HCTI’s broader AI, digital health, and customer-engagement platform activity.
Healthcare Triangle, Inc. held a virtual annual meeting on July 17, 2026, where holders of 20,386,046 shares, representing 92.55% of the 22,027,783 shares entitled to vote, were present or represented. Shareholders elected four directors for one-year terms through 2027 and ratified SRCO Professional Corporation as independent registered public accounting firm for the year ending December 31, 2026.
Shareholders approved an amendment to the 2020 Stock Incentive Plan to add automatic annual share increases beginning fiscal 2026, equal to the greater of 2,000,000 shares, 20% of outstanding common stock, or an amount set by the plan administrator, with the amendment running until December 31, 2030. They also approved multiple equity-related items: issuance of 2,828,167 shares under a settlement with SecureKloud Technologies Ltd.; issuance of up to 11,869,397 shares in the Teyame transaction; potential issuances above the Exchange Cap under an ELOC Purchase Agreement with Hudson Global Ventures, LLC; issuances underlying original issue discount senior secured convertible debentures; future below-Minimum Price issuances under Nasdaq Listing Rule 5635(d); and the ability to adjourn or postpone the meeting to solicit additional proxies.
Healthcare Triangle, Inc. is registering 28,000,000 shares of common stock for resale by Hudson Global Ventures, LLC under an equity purchase (ELOC) arrangement. This includes up to 27,950,000 ELOC Shares plus 50,000 shares issuable on exercise of a warrant at $0.00001 per share.
The company is not selling shares in this resale and will not receive proceeds from Hudson’s sales, but may raise up to $50,000,000 by directing Hudson to buy shares over about 36 months at a discount to market. Common stock outstanding would be 30,027,783 shares if all ELOC Shares and warrant shares are issued.
Healthcare Triangle highlights dilution and overhang risks from the ELOC and notes broad discretion over any ELOC proceeds, intended for general corporate purposes including operating needs, R&D and acquisitions. Recent moves include a $50.0 million Teyamé/Datono acquisition, a 1-for-60 reverse split and a $4.235 million convertible note financing.
Healthcare Triangle, Inc. filed a registration statement covering the resale by Hudson Global Ventures, LLC of up to 28,000,000 shares of common stock. These consist of up to 27,950,000 ELOC Shares that may be issued under a June 12, 2026 Equity Purchase Agreement and 50,000 shares issuable upon exercise of a warrant granted as a commitment fee.
The company is not selling shares in this offering and will receive no proceeds from resales, but may raise up to $50,000,000 in gross proceeds by selling shares to Hudson under the equity line, at prices based on future market trading. Assuming all ELOC Shares and warrant shares are issued, common stock outstanding would be 30,027,783 shares. The stock trades on Nasdaq Capital Market under the symbol HCTI, and closed at $1.70 on July 8, 2026.
Healthcare Triangle, Inc. registers 28,000,000 shares of Common Stock for resale by Hudson Global Ventures, LLC. The resale registration covers up to 27,950,000 ELOC Shares and 50,000 Exercise Shares underlying a warrant issued in connection with an Equity Line of Credit Purchase Agreement (the ELOC Purchase Agreement). The Company will not receive proceeds from shares resold by the Selling Stockholder; however, the Company may receive up to $50,000,000 in aggregate gross proceeds if it elects to sell shares to the Selling Stockholder under the ELOC Purchase Agreement, which is subject to customary conditions and a 4.99% beneficial ownership limitation. The Company’s Common Stock is listed on the Nasdaq Capital Market under the symbol HCTI.
Healthcare Triangle, Inc. is holding a virtual 2026 annual meeting on July 17, 2026 to elect four directors, ratify its auditor and vote on several major share-related proposals. Stockholders are asked to approve an automatic annual increase to the 2020 Stock Incentive Plan, broad authority for future discounted 20% Issuances under Nasdaq rules, and multiple specific share issuances tied to acquisitions and financings.
These include 2,828,167 settlement shares to SecureKloud’s affiliate, up to 11,869,397 shares for the Teyame acquisition, potential issuance of stock above a 405,354-share exchange cap under a $50 million equity line of credit with Hudson Global, and conversion shares for $4.32 million of original issue discount senior secured convertible debentures that could result in up to 9,370,120 new shares. With only 2,027,783 common shares and 20,000 super-voting preferred shares outstanding as of June 8, 2026, these approvals could significantly dilute existing holders and may affect voting control.
Healthcare Triangle, Inc. outlines several equity transactions tied to prior acquisitions and corporate agreements. The company agreed to issue 2,828,167 common shares to SecureKloud Technologies Ltd. (or its nominee) in exchange for all Series B Convertible Preferred Stock previously issued as consideration for an asset transfer, with the closing subject to stockholder approval under Nasdaq Rule 5635(b).
The company also amended a share purchase agreement for Teyame AI, changing the consideration to $12,000,000 of restricted common stock and 18,000 shares of a new preferred series, each with a stated value of $1,000 and convertible, at the company’s option after stockholder approval under Nasdaq Rule 5635(a), into 430.21 common shares. A pre-funded warrant with a $0.00001 exercise price may be used instead of excess common shares above the 19.99% cap.
In connection with these transactions, the company designated 23,000 shares of Series C Convertible Preferred Stock, each with a $1,000 stated value and a 430.2-share conversion ratio at the company’s option after stockholder approval. All related securities, including exchange shares, preferred stock, common stock consideration and the warrant, rely on private-offering exemptions under Section 4(a)(2) and Regulation D.
Healthcare Triangle, Inc. seeks stockholder approval at a virtual annual meeting on to be held on to elect four directors and approve a slate of Nasdaq-related financing and equity issuance proposals. Key votes include an amendment to the 2020 Stock Incentive Plan, approval of a 2,915,656 share settlement issuance, approval to issue up to 12,200,000 shares under the Teyame acquisition, approval related to an up-to $50,000,000 equity line (ELOC), and approval of shares underlying OID senior secured convertible debentures.
The Board unanimously recommends voting FOR all proposals, including ratifying SRCO as auditors and authorizing adjournments to solicit additional proxies. The proxy materials state the record date is June 8, 2026 and the meeting is on July 17, 2026. Voting options and quorum rules are described in the proxy materials.
Healthcare Triangle, Inc. entered into two major financing arrangements. It completed a private placement of 15% original issue discount senior convertible promissory notes with aggregate principal of $4.235 million, generating approximately $3.6 million in gross proceeds, maturing on December 12, 2026.
The notes are convertible after six months at 85% of the three-day volume-weighted average price of the common stock, subject to a $0.452 per share floor and Nasdaq shareholder approval limits. The company also signed an Equity Purchase Agreement with Hudson Global Ventures allowing it to require purchases of up to $50,000,000 of common stock over up to 36 months, with pricing at a 6% discount to specified market prices and a 4.99% beneficial ownership cap.